Candel Therapeutics (CADL) Projected to Post Quarterly Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL opened at $5.11 on Wednesday. The company has a market capitalization of $280.54 million, a P/E ratio of -8.96 and a beta of -0.91. Candel Therapeutics has a 1-year low of $4.25 and a 1-year high of $9.08. The firm’s 50 day simple moving average is $5.63 and its two-hundred day simple moving average is $5.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25.

Insiders Place Their Bets

In related news, Director Paul B. Manning acquired 550,458 shares of the stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the completion of the purchase, the director owned 2,763,527 shares of the company’s stock, valued at approximately $15,061,222.15. This represents a 24.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 16.60% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after acquiring an additional 219,563 shares during the period. Geode Capital Management LLC grew its holdings in shares of Candel Therapeutics by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock worth $5,524,000 after buying an additional 49,315 shares in the last quarter. State Street Corp raised its holdings in Candel Therapeutics by 15.0% in the 4th quarter. State Street Corp now owns 792,218 shares of the company’s stock valued at $4,476,000 after acquiring an additional 103,452 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Candel Therapeutics in the third quarter valued at approximately $697,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Candel Therapeutics by 180.9% during the 4th quarter. Wells Fargo & Company MN now owns 73,899 shares of the company’s stock worth $418,000 after acquiring an additional 47,588 shares during the period. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Wall Street Analysts Forecast Growth

CADL has been the topic of a number of analyst reports. Stephens restated an “overweight” rating and set a $15.00 target price on shares of Candel Therapeutics in a research note on Monday, December 8th. Zacks Research cut shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Citigroup cut their target price on Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.